卵巢癌复发治疗的研究进展-肿瘤药学.PDF

肿瘤药学 2019 年 4 月第 9 卷第 2 期　Anti-tumor Pharmacy, April 2019, Vol. 9, No. 2 - 189 - ●综　　述● 卵巢癌复发治疗的研究进展★ 1 2 * 1 2 刘　姗 ，王　静 ，刘　路 ，欧阳佩琳 1 2 （南华大学，湖南 衡 阳，42 100 1； 湖南省肿瘤 医院/ 中南大学湘雅 医学院附属肿瘤 医院，湖南 长沙，4 100 13 ） 摘要：卵巢癌是妇科常见的恶性肿瘤，其病死率及复发率均居妇科恶性肿瘤之首，对于复发性卵巢癌的治疗一直是研究 的热点。大量临床试验研究了二次细胞减灭术、化疗和靶向药物等复发性卵巢癌的治疗方案，尤其是对贝伐珠单抗、PARP 酶 抑制剂等靶向治疗方案的研究，取得了突破性进展。多种 PARP 酶抑制剂药物获准用于临床，为复发性卵巢癌的治疗提供了 更多的选择。本文主要就卵巢癌复发治疗的研究进展进行了综述。 关键词：复发性卵巢癌；二次减灭术；靶向药物；贝伐珠单抗；PARP 酶抑制剂 中图分类号：R737.31　文献标识码 ：A　文章编号：2095-1264（2019）02-0189-04 doi：10.3969/j.issn.2095-1264.2019.02.03 Research Progress of the Treatment of Recurrent Ovarian Cancer ★ 1 2* 1 2 LI U Shan , WANG Jing , LI U Lu , OUYANG Peilin 1 2 ( University of South China, Hengyang, Hunan, 421001, China; Hunan Cancer Hosp ital / The Aff iliated Cancer Hosp ital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China) Abstract: Ovarian cancer is a common gynecological cancer. Its mortality and recurrence rate ranks the first in gynecological cancers. It has become a hotspot to research the treatments of recurrent ovarian cancer. A large number of clinical trials have investigated the treatments of recur- rent ovarian cancer such as secondary cytoreductive surgery, chemotherapy and targeted medicine. In particular, breakthroughs have been made in targeted therapies like bevacizumab and PARP inhibitors. A variety of PARP inhibitor medicines have been approved for clinic, providing more treatment choices for recurrent ovarian cancer. Thi